Latest News

Concerns about potential health risks associated with low-level exposures to PFAS, along with their widespread uses and reported detections in various environmental media and products, are triggering regulation, litigation, and an urgent need to apply the best available science in evaluating the exposure, toxicology, and epidemiology to characterize potential human health risks. ToxStrategies and EpidStrategies have scientific expertise and advanced technical resources to assist clients in navigating the scientific environment and growing regulatory labyrinth associated read more…

A team of ToxStrategies and EpidStrategies scientists are authors on a manuscript being published in Regulatory Toxicology and Pharmacology. The study examines current practices for assessing risk associated with environmental exposure to hexavalent chromium, comparing approaches based on margin of exposure to those using linear extrapolation. The authors assert that regulatory lung cancer potency estimates for Cr(VI) are based on outdated research, whereas more current mechanistic data support an epigenetic role for Cr(VI) and a read more…

ToxStrategies scientist Kara Franke presented a session on optimizing industrial hygiene data collection and management to inform the US EPA in the TSCA risk evaluation process at the 2021 AIHce EXP virtual conference. The presentation highlighted issues that included: Ensuring appropriate analytical limits of detection Best practices for record-keeping Collecting robust, high-quality data that represent not just high-risk workers but all workers with potential exposure. The talk was titled “Updating your Exposure Assessment Strategy to read more…

Cannabidiol (CBD) and other hemp-derived products continue to gain attention from the FDA and consumers. A ToxStrategies team led by Dr. Rayetta Henderson is continuing work on a systematic mapping of published literature related to CBD and safety. Studies will be categorized by CBD or related substance type, route of exposure, study model, and health outcome(s) (e.g., neurological, reproductive, etc.), and classified as beneficial or adverse. A preliminary analysis of the data was presented at the 2020 Society of read more…

Dr. John M. Rogers, ToxStrategies Senior Consultant, has been awarded the 2021 Edward W. Carney Distinguished Service Award by the Society for Birth Defects Research and Prevention (BDRP, established in 1960 as the Teratology Society). This award honors Dr. Edward W. Carney, Past President of BDRP, for his exemplary dedication and service to the Society and the field of teratology. The Edward W. Carney Distinguished Service Award recognizes an individual who has provided distinguished service read more…

EpidStrategies, a division of ToxStrategies, Inc., is excited to be participating in the European Hematology Association Virtual Congress, which will be held virtually from June 9th through 17th, 2021. Naushin Hooda, Xiaohui Jiang, and Gina Nicholson will present two virtual posters during the congress, on Friday, June 11, at 09:00 CEST. The posters are titled, “Healthcare resource utilization among patients with cold agglutinin disease in Denmark” and “Increased antidepressant use among newly diagnosed patients with cold read more…

ToxStrategies is pleased to announce that John M. Rogers, Ph.D., has joined our Health Sciences Practice, following a distinguished career with the U.S. EPA. Dr. Rogers brings more than 40 years of experience in the areas of developmental and reproductive toxicology, further strengthening the body of expertise that we offer our clients. Dr. Rogers’ experience includes evaluating and advising on animal and in vitro toxicology research to support U.S. EPA decision-making. He also brings a wealth of read more…

ToxStrategies Information Specialist Ms. Seneca Fitch is among a group of scientists from the regulatory community, academia, the pharmaceutical industry, and consulting who have published an article in Scientific Reports (an open-access publication of the journal Nature). The paper investigates why some new drugs, having survived the rigorous process of animal and human testing necessary to bring them to market, end up causing unexpected, and sometimes severe, adverse drug reactions in the wider patient population (killing more than 10,000 patients annually read more…